Understand the source comparison
Do Peptides Help with Chronic Fatigue: Clinical Evidence Comparison
Thymosin alpha-1 Immune modulation via T-cell regulation 5 pilot studies (n=142 total); 1 double-blind RCT in adjacent condition 0.8–3.2mg SC 2–3×/week for 12–16 weeks Strongest evidence base; multiple trials show 22–34% fatigue reduction but lack large RCTs T
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin alpha-1
- Immune modulation via T-cell regulation
- 5 pilot studies (n=142 total); 1 double-blind RCT in adjacent condition
- 0.8–3.2mg SC 2–3×/week for 12–16 weeks
- Strongest evidence base; multiple trials show 22–34% fatigue reduction but lack large RCTs
- Thymalin
- Thymic peptide complex; immune coordination
- Observational data only; no controlled trials in ME/CFS
- 5–10mg SC daily for 5–10 day cycles
- Preclinical interest; human validation absent
- SS-31 (Elamipretide)
- Mitochondrial cardiolipin stabilisation; ATP synthesis
- Phase 2 trials in heart failure/mitochondrial disease; zero trials for chronic fatigue
- 40mg IV in published cardiology trials
- Strong mitochondrial mechanism; no chronic fatigue-specific studies
- MK 677
- Growth hormone secretagogue; ghrelin receptor agonist
- Zero controlled trials for fatigue; anecdotal protocols only
- 12.5–25mg oral daily
- Indirect sleep/metabolic effects; no fatigue trials exist
- Cerebrolysin
- Neurotrophic signaling; cognitive support
- 1 observational study in TBI-related fatigue (n=18)
- 10–30mL IV over 10–20 sessions
- Weak evidence; unvalidated outcome measures